Royce & Associates LP raised its stake in Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) by 23.5% during the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 1,453,456 shares of the biotechnology company’s stock after purchasing an additional 276,200 shares during the period. Royce & Associates LP’s holdings in Progenics Pharmaceuticals were worth $9,113,000 as of its most recent SEC filing.
Other institutional investors also recently made changes to their positions in the company. Commonwealth of Pennsylvania Public School Empls Retrmt SYS purchased a new position in Progenics Pharmaceuticals in the 2nd quarter valued at $125,000. NumerixS Investment Technologies Inc grew its position in Progenics Pharmaceuticals by 163.3% in the 2nd quarter. NumerixS Investment Technologies Inc now owns 15,800 shares of the biotechnology company’s stock valued at $128,000 after buying an additional 9,800 shares during the last quarter. Trexquant Investment LP purchased a new position in Progenics Pharmaceuticals in the 2nd quarter valued at $281,000. Virtu Financial LLC purchased a new position in Progenics Pharmaceuticals in the 3rd quarter valued at $327,000. Finally, Raymond James & Associates grew its position in Progenics Pharmaceuticals by 24.3% in the 2nd quarter. Raymond James & Associates now owns 71,586 shares of the biotechnology company’s stock valued at $576,000 after buying an additional 14,008 shares during the last quarter. Institutional investors own 92.09% of the company’s stock.
Progenics Pharmaceuticals stock opened at $4.56 on Friday. Progenics Pharmaceuticals, Inc. has a one year low of $4.47 and a one year high of $9.42. The company has a debt-to-equity ratio of 0.33, a current ratio of 9.51 and a quick ratio of 9.51.
Progenics Pharmaceuticals (NASDAQ:PGNX) last released its earnings results on Thursday, November 8th. The biotechnology company reported ($0.09) EPS for the quarter, beating analysts’ consensus estimates of ($0.18) by $0.09. Progenics Pharmaceuticals had a negative return on equity of 66.86% and a negative net margin of 341.78%. The company had revenue of $5.32 million during the quarter, compared to the consensus estimate of $4.14 million. Sell-side analysts anticipate that Progenics Pharmaceuticals, Inc. will post -0.76 EPS for the current fiscal year.
A number of equities analysts recently weighed in on the stock. ValuEngine lowered shares of Progenics Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, August 29th. BidaskClub lowered shares of Progenics Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Wednesday, September 5th. Zacks Investment Research upgraded shares of Progenics Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Tuesday, September 11th. Finally, Needham & Company LLC lowered shares of Progenics Pharmaceuticals from a “strong-buy” rating to a “buy” rating and lowered their price objective for the company from $16.00 to $12.00 in a research report on Thursday, September 13th. One analyst has rated the stock with a sell rating, one has assigned a hold rating and five have issued a buy rating to the stock. Progenics Pharmaceuticals presently has a consensus rating of “Buy” and an average target price of $10.65.
WARNING: This piece was reported by The Lincolnian Online and is the sole property of of The Lincolnian Online. If you are accessing this piece on another publication, it was copied illegally and reposted in violation of US & international copyright legislation. The original version of this piece can be read at https://www.thelincolnianonline.com/2018/12/08/progenics-pharmaceuticals-inc-pgnx-holdings-boosted-by-royce-associates-lp.html.
About Progenics Pharmaceuticals
Progenics Pharmaceuticals, Inc develops medicines and other technologies to target and treat cancer in the United States and internationally. The company's primary clinical-stage product candidates include Azedra, a radiotherapeutic product candidate, which is in Phase IIb clinical trial under special protocol assessment for the treatment of malignant, recurrent, and/or unresectable pheochromocytoma and paraganglioma; 1404, a technetium-99m labeled small molecule, which is in Phase III clinical trial that acts as an imaging agent to diagnose and detect prostate cancer, as well as soft tissue and bone metastases; and PyL, a fluorinated prostate specific membrane antigen (PSMA)-targeted positron emission topography (PET) imaging agent for prostate cancer.
See Also: What is Liquidity?
Want to see what other hedge funds are holding PGNX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX).
Receive News & Ratings for Progenics Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Progenics Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.